CStone submits new drug application for the targeted therapy avapritinib in Taiwan for the treatment of adults with advanced PDGFRA exon 18 mutant gastrointestinal stromal tumor
- Friday, March 27, 2020, 7:07
- Finance
- Add a comment
SUZHOU, China, March 27, 2020 /PRNewswire/ — CStone Pharmaceuticals (“CStone” or the “Company”, HKEX: 2616) today announced that the Company has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for avapritinib, a precision therapy being developed…
About the Author
adminasapcorp has written 39038 stories on this site.